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Abstract 
Pulmonary hypertension (PH) is classified into 5 groups based on disease etiology but there is 
only limited information on the prognostic value of exercise testing in non-Group 1 PH.  In 
Group 1 PH the incremental shuttle walking test (ISWT) distance has been shown to correlate 
with pulmonary hemodynamics and predict survival without a ceiling-effect. This study 
assessed the ISWT in non-group 1 PH. Data were retrieved from the ASPIRE registry 
(Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre) for 
consecutive patients diagnosed with PH. Patients were required to have been systematically 
assessed as Group 2-5 PH and to have a baseline ISWT within 3 months of cardiac 
catheterization. Patients were stratified according to incremental shuttle walk test distance 
(ISWD) and ISWT distance percent predicted (ISWD%pred). 479 patients with non-Group 1 
PH were identified.  ISWD and ISWD%pred correlated significantly with symptoms and 
hemodynamic severity. ISWD and ISWD%pred predicted survival with no ceiling-effect. The 
test was prognostic in Groups 2, 3 and 4.   ISWD and ISWD%pred and change in ISWD and 
ISWD%pred at 1 year were all significant predictors of outcome. In patients with non-Group 
1 PH the Incremental Shuttle Walk Test is a simple non-invasive test that is easy to perform, 
is predictive of survival at baseline and follow-up, reflects change and can be used in the 
assessment of PH of any etiology. 
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Introduction 
Many mechanisms can lead to an elevation of resting mean pulmonary artery pressure 
(mPAP). Pulmonary hypertension (PH) is classified into 5 groups according to distinct 
pathophysiological characteristics.1  Group 1 (pulmonary arterial hypertension (PAH) ) has 
been the most studied but PH due to other causes is more common.2,3  Whatever the cause, 
pulmonary hypertension places a substantial burden on the patient, contributing to the 
severity of disease and affecting quality of life.4-9As exercise limitation is a significant 
symptom in PH, it is important that exercise tests used for the assessment of physical 
functioning reflect the severity of disease. Currently two exercise tests are mainly used in 
patients with PAH: the six-minute walking test (6MWT) which is an un-encouraged field test 
and cadio-pulmonary exercise test (CPET) which is an incremental maximal test.  
Because of its simplicity the 6MWT is the test most frequently used to monitor patients in the 
clinic and assess the efficacy of new therapies. However, concerns have been raised 
regarding the use of the 6MWT.10-13 In milder disease a ceiling-effect has been noted where 
6MWT distance (6MWD) no longer reflects maximal oxygen aerobic capacity (VO2peak)14-16 
or disease severity17 and the test has been shown to be unresponsive to clinically important 
changes in haemodynamic parameters.17-20 whilst, change in 6MWD does not explain a large 
proportion of observed treatment effect.21-23   Very few studies look specifically at the 
prognostic significance of the 6MWT distance in non-group 1 patients.24-26 
CPET is a more complex test. It provides information on the aetiology of exercise 
limitation,27 provides prognostic information,28 reflects hemodynamic severity and unlike the 
6MWT reflects VO2peak even in mild disease.  However, due to its complexity, routine use 
of CPET is challenging and when used in a randomised controlled trial it was unable to 
demonstrate a treatment effect.29   In addition the prognostic utility of CPET variables may 
also differ according to the etiology of PAH.30 
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The Incremental Shuttle Walk Test (ISWT) is an externally-paced symptom-limited test 
requiring the patient to walk around a 10 m course. The speed increases every minute and 
patients continue walking until they can no longer keep pace with the signal. Strong 
correlations are found between distance walked and VO2 peak in patients with different 
diseases, including heart failure.31, 32 In addition to correlating more strongly than the 6MWT 
with VO2peak, the ISWT has been found to be  a better predictor of survival than the 6MWT 
in chronic heart failure.33  
The ISWT shares benefits of both the 6MWT and CPET. It is simple and quick to 
perform but also has the benefits of an incremental nature to maximum exercise capacity. In 
addition, as the test uses a 10m course rather than the 30m corridor required for the 6MWT, it 
is easy to perform in the clinical environment.  Because of these advantages the ISWT has 
been proposed as an alternative field walking test to the 6MWT in PAH,34, 35  and a small 
study looking specifically at patients with pulmonary arterial hypertension noted that ISWT  
distance (ISWD) correlated more closely with peak oxygen consumption than 6MWT 
distance.36  
Using data from the ASPIRE registry we recently demonstrated in patients with PAH that 
distance walked during the ISWT correlated with pulmonary hemodynamics, WHO 
functional class and resting Borg score and predicted prognosis both at baseline and at 
subsequent follow-up, all without a ceiling-effect.37 This study now assesses the usefulness of 
the ISWT in patients with non-group 1 PH. 
 
Methods 
 
Data were retrieved from the ASPIRE registry (Assessing the Spectrum of Pulmonary 
hypertension Identified at a REferral centre) for consecutive patients diagnosed with 
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pulmonary hypertension, defined as having an mPAP 25 mmHg, between 2001-10, as 
previously described.38  
For inclusion patients were required to have been systematically assessed as Group 2-
5 PH (PH due to: left heart disease, group 2; lung disease and/or hypoxemia, group 3; chronic 
thromboembolic PH, group 4; and  unclear or multifactorial aetiologies, group 5) and to have 
a baseline ISWT within 3 months of cardiac catheterization. Patients with multiple potential 
causes of PH were excluded to allow comparisons between single phenotypes; e.g. patients 
with  connective disease with left heart disease or lung disease or patients with CTEPH and 
significant co-existing left heart disease or lung disease, were excluded (Figure 1). Ethical 
approval was granted by the North Sheffield Research Ethics Committee (Reference No. 
06/Q2308/8). 
Incremental Shuttle Walk Test 
The ISWT was performed according to the method of Singh et al.39 Using a standardised 
recording, patients were asked to walk as far as possible around the 10m course keeping in 
time to the audio signal until they were too breathless or could no longer keep up with the 
speed. The initial walking speed was 0.50 m/s and this increased incrementally every minute 
to a maximum of 2.37 m/s. The primary measure was distance walked.  In addition, 
breathlessness was measured at rest prior to the ISWT and at the end of the test. Percent 
predicted ISWT distance (ISWT%pred) was calculated for each patient based on sex, age and 
BMI using the equation derived by Probst et al.40 Patients were recorded as walking 0 m if 
they could not complete 1 shuttle length in the required time whilst breathing room air.  A 
small proportion of patients who were on high flow O2 who were unable to remove their 
oxygen and attempt to walk along the corridor were assigned a walking distance of 0 m, if in 
the opinion of the physiologist they were unable to complete 1 shuttle length. 
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Follow-up 
Survival status was ascertained at the census point via the NHS enhanced reporting service. 
Data were collected for patients who had had a repeat assessment at 12 months (+/-2 months) 
post-diagnosis.  
Statistical analysis  
Statistical analysis was performed using IBM SPSS Statistics v19 (SPSS, Chicago, 
IL, USA). Continuous variables were described by mean±standard deviation.  If data was not 
normally distributed, results were presented as median±interquartile range. Categorical 
variables are presented as n(%). Pearsons correlation test was used to assess correlations 
between ISWD or ISWD%pred and hemodynamic parameters and was tested for 2-sided 
significance. Student t test and Mann Whitney U test were used to compare groups.     
Multiple comparisons between groups were performed using ANOVA. Event (death or 
transplantation)-free survival from date of diagnosis was estimated using the KaplanMeier 
method with comparison between groups performed by the log-rank test. The accuracy of the 
prognostic parameters was estimated using receiver operating characteristic (ROC) curves. A 
p-value of <0.05 was deemed statistically significant.   
Stratification of patients  
A model with 5 pre-specified Bands based on walking distance/maximal walking 
speed was used as previously described for Group 1 PAH.37 Band 1: 0-30m; Band 2: 40-
120m; Band 3: 130-250m ; Band 4: 260-420m; Band 5: 430-1020m.  ISWD%pred was 
similarly stratified into 5 Bands. Band 1; 0-10%; Band 2: >10-20%; Band 3: >20-35%, Band 
4: >35-60%; Band 5: >60%. At follow-up improvement in ISWD was defined as an increase 
>40m, decline a decrease >20m and the remaining patients defined as stable. Improvement in 
ISWD%pred was defined as an increase in ISWD%pred of >10%, decline a decrease of >4% 
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ISWD%pred and the remaining patients defined as stable. Patients were also grouped by age 
to assess the utility of the ISWT in more elderly patients.  
 
Results  
 
Four hundred and seventy nine patients with non-group 1 pulmonary hypertension 
were identified (Fig. 1). Patient characteristics are shown in Table 1. Data completeness was 
high (>90%). Median distance walked at baseline was 120m and median time to complete the 
walk was 3.2 minutes. Details of treatment are given in Supplementary material Table S1 A 
Disease severity 
ISWD and ISWD%pred correlated significantly both with the severity of symptoms (Borg 
score and World Health Organization (WHO) functional class), and with haemodynamic 
parameters including, right atrial pressure (RAP), pulmonary vascular resistance (PVR), 
cardiac output, cardiac index and mixed venous oxygen saturation, (p all<0.001) mPAP also 
correlated with ISWD (p=0.025) and ISWD%pred(<0.001). One-way ANOVA demonstrated 
highly significant relationships (p<0.001) across all ISWD and ISWD%pred Bands with 
WHO functional class, baseline resting Borg score, and baseline pulmonary hemodynamic 
parameters (Fig. 2). Analysing etiological groups separately, in Groups 3 and 4 ISWD and 
ISWD%pred correlated significantly with mPAP, mRAP, CI, PVR and WHO FC. In addition 
in Group 4, ISWD and ISWD%pred also correlated with SmVO2.  In Group 2 ISWD 
correlated significantly with only SmVO2 and WHO FC whilst ISWD%pred correlated with 
mPAP and WHO FC. See Supplemetary Table S2. 
Baseline ISWD and survival 
Kaplan-Meier survival analysis demonstrated that both baseline ISWD and baseline 
ISWD%pred predicted survival with no ceiling-effect across the 5 Bands (both p<0.001) 
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(Fig. 3).  ROC analysis found no significant difference in the predictive power for long-term 
survival between ISWD and ISWD%pred (AUROC 0.693 (0.646-0.739) and 0.703 (0.657-
0.750) respectively). Analysing the PH Groups separately, Kaplan-Meier survival analysis 
demonstrated that both baseline ISWD and baseline ISWD%pred predicted survival in 
Groups 2, 3 and 4 (p all<0.005), analysis was not performed in Group 5 due to small 
numbers, n=27) (Fig. 4). In addition to baseline ISWD predicting long-term outcome in all 
patients with CTEPH it also predicted outcome in patients undergoing (n=94, p=0.045) and 
not undergoing surgery (n=108, p=0.008), during the study period. ISWD%pred also 
predicted outcome for all CTEPH patients (p=0.002) and patients not undergoing surgery 
(p=0.009) but was not a significant predictor in those who had had surgery, 
Follow-up  
Follow-up data was available for 150 patients at one-year follow up.  Mean change in ISWD 
(ǻ,6:') was +37±128m (p=0.001, paired t test).  Kaplan-Meier analysis showed that the 
ISWD at 1 year, were ISWD%pred at 1year were significant predictors of outcome (p 
both=<0.001). Sub-analysis of data on CTEPH patients (n=93, 49 having endarterectomy) showed 
that patients ISWD predicted long-term survival (p=0.04). 
Age  
)LIW\VHYHQSHUFHQWRISDWLHQWVZHUH\HDUVROGPatient characteristics stratified by age are 
shown in table 2.  At baseline mPAP, CI, and SmvO2 were significantly lower in the older 
patients whilst there was no significant difference in PVR and mRAP,  Those DJHG\HDUV 
presented with more severe functional decline with only 12% being in WHO FC 1 or 2  
compared to 24% of patients aged <65 years (p=0.002). This was reflected by a significantly 
lower ISWD and lower ISWD%pred. The distribution of patients in the distance bands also 
differed: of the older patients 9% walked >250m and 17% walked >35% predicted ISWD 
compared with 32% and 26% respectively in the younger patients. Nonetheless, although 
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overall survival in older patients was worse than in patients aged <65 years (Fig. 5A),   ISWD 
and ISWD%pred were significant predictors of long-term survival (Fig. 5 B and C) and were 
as effective predictors of one-year survival in the elderly (area under the ROC curve 
(AUROC(9)5%CI)  0.670 (0.557-0.776) and 0.701 (0.600-0.802), respectively) as for the 
younger patients (0.678 (0. 587-0.770) and 0.707(0.621-0.792). Cox multivariate survival 
analysis including either ISWD or ISWD%pred, hemodynamic parameters mRAP,  mPAP, 
PVR, CI and SmVO2, age, sex and WHOFC I, II vs WHOFC III, IV, showed both ISWD or 
ISWD%pred to be independent predictors of outcome in both age groups. As well as 
predicting survival in older patients, ISWD and ISWD%pred also reflected disease severity in 
the elderly group, correlating significantly (all p<0.005) with mRAP,  mPAP, PVR, CI and 
SmVO2  and WHO FC (See Supplementay material Table S2).  
 
Discussion  
 
This study is the first to show that in non-Group 1 PH patients that distance walked using the 
incremental shuttle walking test, whether absolute or expressed as a percentage of predicted 
walking distance, correlates with baseline pulmonary hemodynamics, WHO functional class 
and resting Borg score and predicts prognosis both at baseline and at subsequent follow-up. 
Furthermore this test is prognostic of survival when the data is analysed as a whole group, in 
separate aetiological groups and older patients aged \HDUV.  Follow-up ISWTT distance 
had prognostic value, emphasising the need for assessment at multiple time-points.41 
Patients with Group 2-5 PH represent a substantial percentage of the patients referred 
to Specialist PH centres,26, 38 however with the exception of Group 4 (CTEPH) little has been 
published previously on the predictive significance of exercise tests in non-group 1 
pulmonary hypertension.  There have been some studies of the predictive significance of the 
6MWT in single non-group 1 PH sub-groups. A study of patients with PH related to heart 
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failure with preserved ejection fraction found that 6MWD was an independent predictor of 
hospitalization and/or death for cardiac reasons.24 It has also been shown that shown that 6-
minute walk distance reflected the clinical and hemodynamic severity of disease in patients 
with chronic thromboembolic pulmonary hypertension and the change in the 6-minute walk 
distance correlated with the observed clinical and hemodynamic improvement.26  One small 
study looking at the full range of  Group 2-5 PH found, in 60 patients, that a 6MWD <400m 
was associate with a higher risk for death.  Numbers were too small to analyse etiological 
groups separately and follow-up data were not available.25Analysis of survival data from the 
Giessen Pulmonary Hypertension Registry, the largest single centre PH registry, found that 
6MWT distance was a predictor of outcome across all groups of PH, although the results 
were most robust in Group 1.26  In Groups 2, 3 and 4 they found that survival of the top 
quartile of patients  who walked >390m was not significantly better than patients in the 3rd 
quartile who walked  311-390m.  Our study demonstrates the utility of a field exercise test in 
different pulmonary hypertension diagnostic groups and across the range of disease severity 
with no ceiling-effect. 
Currently, guidelines do not recommend any PAH specific drugs for the treatment of 
patients with Group 2-5 PH but to consider trials of therapy in carefully selected patients with 
severe pulmonary hypertension.43 Nonetheless, studies have shown a significant number of 
these patients do receive PAH targeted therapies44, 45 and the need to evaluate therapies in 
Groups 2 and 3 has been highlighted.44-47 We have demonstrated that the ISWT is a useful 
tool for assessing exercise capacity for clinical monitoring and may have utility as an 
endpoint in trials of targeted therapies for non-group 1 PH. 
Limitations of study 
The models of prediction using the ISWT were based on retrospective data from a single 
Specialist PH centre. Although the numbers were high at baseline (479) and allowed analysis 
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of Groups 2 to 4 there were insufficient numbers to allow sub-group analysis. In addition 
only 150 patients were re-evaluated at 1 year, limiting follow-up analysis, since it is not the 
policy of the centre to follow-up Group 2-5 patients unless they are receiving a specific 
interventions. For patient with CTEPH, surgery is a potential confounding factor influencing 
outcome. Nonetheless at baseline ISWT distance predicted outcome for patients both 
undergoing and not undergoing surgery.  
The data in this Registry was collected when pulmonary hypertension was defined as a mPAP 
PP+J7KHGHILQLWLRQRISXOPRQDU\K\SHUWHQVLRQKDVUHFHQWO\EHHQXSGDWHGWRP3$3 > 
20 mmHg.48  Further work is required to evaluate the utility of the ISWT in patients with 
mPAP>20 mmHg and <25mmHg.  
In addition, the nature of this study precludes any comparison with the current 
standard field walking test used in the evaluation of PH (6-minute walking test). However, 
this study further highlights the utility of the ISWT in the evaluation of patients with PH. 
Conclusion 
The Incremental Shuttle Walk Test is a simple non-invasive test that is easy to 
perform in patients with non-Group 1 PH, is predictive of survival at baseline and follow-up, 
and reflects change. We have demonstrated that the ISWT can be used to predict outcome in 
both group 1 and non-Group 1 pulmonary hypertension. 
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Figure Legends 
Fig. 1. The study cohort. PH: pulmonary hypertension; ISWT: Incremental shuttle walk test;  
CTD: connective tissue disease; PAH: pulmonary arterial hypertension; 
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Fig. 2.  Relationship between baseline Incremental Shuttle Walk Test Band and:  CI: cardiac 
index; PVR: pulmonary vascular resistance, RAP: right atrial pressure; SmVO2: mixed venous 
oxygen saturation; %WHO Class 1+2: percentage of patients in World Health Organisation 
functional class I and II (all p<0.001). A) Band 1 ISWD m: 10-30; Band 2: 40-120; Band 3: 130-
250; Band 4: 260-420; Band 5: 430-1020.   B) ISWD%predicted Band 1: 0-10; Band 2: >10-20; 
Band 3: >20-35; Band 4: >35-60; Band 5: >60. 
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Fig. 3. Kaplan-Meier survival analysis stratified according to baseline A) Incremental shuttle walk 
distance and B) Incremental shuttle walk distance percent predicted. 
DOI: 10.1177_2045894019848649 
 
23 
 
 
Fig. 4. Kaplan-Meier survival analysis stratified according to baseline Incremental shuttle walk 
distance in patients with PH due to: A) Left heart disease; B) Lung disease and C) CTEPH and 
stratified by Incremental shuttle walk distance percent predicted in patients with PH due to: D) 
Left heart disease; E) Lung disease and F) CTEPH. 
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Table 1. Patient characteristics 
 
Presented as mean±SD for parametric data and * median (interquartile range) for 
nonparametric data. mRAP: mean right atrial pressure; mPAP: mean pulmonary artery 
pressure; PWP: pulmonary wedge pressure; LHD: left heart disease; CTEPH: chronic 
thromboembolic pulmonary hypertension; CI: cardiac index;  PVR: pulmonary vascular 
resistance; SmvO2: mixed venous oxygen saturation; FEV1: forced expiratory volume in 1 
second; % pred: % predicted; FVC: forced vital capacity; TLco: transfer factor of the lung for 
carbon monoxide; ISWT: Incremental Shuttle Walk Test;   
7DEOH3DWLHQWFKDUDFWHULVWLFVLQSDWLHQWVDJHDQG\HDUV 
 
Overall 
 
(n=479) 
Group 2 
LHD 
(n=103) 
Group 3 
Lung 
(n=147) 
Group 4 
CTEPH 
(n=202) 
Group 5 
Unclear 
(n=27) 
Female n (%) 240(50) 69(67) 51(35) 105(52) 15(56) 
Age  years 65±13 70±10 66±11 61±15 58±15 
WHO FC I+II/III+IV 
(%) 
17/83 28/72 12/88 15/85 15/85 
mRAP mmHg * 10.0(8.0) 14.0(9.0) 9.0(6.0) 10.0±(7.0) 11.0(10.0) 
mPAP  mmHg 43±11 39±13 43±12 47±11 43±12 
PWP mmHg 13.8±6.7 23.2±4.3 11.9±5.0 10.6±4.4 10.4±4.2 
CI  L/min/m2 * 2.6(1.1) 2.9(0.8) 2.8(1.3) 2.4(1.0) 2.8(1.5) 
PVR  Wood Unit * 5.8(6.7) 2.7(2.3) 5.36.0) 8.4(6.1) 6.0(6.8) 
SmvO2 (%) 62±9 64±9 65±8 60±8 59±11 
FEV1 %pred 69±23 69±21 55±24 79±18 68±25 
FVC %pred 83±24 78±23 74±27 91±20 81±19 
FEV1/FVC (%) 68±13 71±10 60±17 71±12 68±17 
Tlco %pred 53±21 62±17 34±17 63±16 41±21 
ISWT Distance m * 120(160) 120(150) 80(130) 140(210) 120(160) 
ISWT time minutes * 3.2(2.9) 3.2(2.8) 2.4(2.6) 3.5(3.4) 3.2(2.8) 
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WHO FC: World Health 
Organization functional class; mRAP: mean right atrial pressure; mPAP: mean pulmonary artery 
pressure: CI: cardiac index; PVR: pulmonary vascular resistance; SmvO2: mixed venous oxygen 
saturation; ISWD: incremental shuttle walk distance 
Supplemental Material 
Table S1 . Treatment of patients 
A) Baseline patients 
 
Diagnostic Group          Treatment 
 
 Frequency Percent 
LHD-PH NO 
CTD 
 Calcium channel blocker 1 1.0 
None 96 93.2 
oral monotherapy 6 5.8 
Total 103 100.0 
LUNG-PH NO 
CTD 
 Calcium channel blocker 1 0.7 
None 85 57.8 
oral dual therapy 6 4.1 
oral monotherapy 48 32.7 
prostenoid mono 2 1.4 
prostenoid  oral 4 2.7 
Unknown 1 0.7 
Total 147 100.0 
 
<65 years 
n=207 
\HDUV 
n=272 
p 
Female n (%) 102(49) 138(51) >0.05 
WHO FC I+II n (%) 49(24) 32(12) <0.001 
mRAP mmHg * 10.0(9.0) 11.0(7.0) >0.05 
mPAP  mmHg 45±12 42±10 0.001 
CI  L/min/m2 * 2.8(0.8) 2.6(0.7) 0.002 
PVR  Wood Unit * 6.0(6.9) 5.8(6.7) >0.05 
SmvO2 (%) 64±9 62±9 0.019 
Wedge mmHg 13±7 14±7 0.029 
ISWD* m 180(203) 80(130) <0.001 
ISWD%pred* 24(24) 16(24) <0.001 
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CTEPH  Pulmonary endarterectomy 94 46.5 
Calcium channel blocker 1 0.5 
None 90 44.6 
oral dual therapy 11 5.4 
oral monotherapy 87 43.1 
prostenoid mono 7 3.5 
prostenoid  oral 2 1.0 
Unknown 4 2.0 
Total 202 100.0 
UNCLEAR   None 10 37.0 
oral dual therapy 2 7.4 
oral monotherapy 10 37.0 
prostenoid  mono 5 18.5 
Total 27 100.0 
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B)  Patients at 1 year follow-up (n=150) 
Diagnostic Group   Treatment 
 
 Frequency Percent 
LHD-PH  None 8 61.5 
oral monotherapy 5 38.5 
LUNG-PH  None 9 26.5 
 oral dual therapy 2 5.9 
 oral monotherapy 21 61.8 
 prostenoid mono 1 2.9 
 prostenoid oral 1 2.9 
All CTEPH  Pulmonary endarterectomy 49 52.6 
 Calcium channel blocker 1 1.1 
 None 42 45.2 
 oral dual therapy 6 6.5 
 oral monotherapy 36 38.7 
 prostenoid mono 4 4.3 
 prost oral 1 1.1 
 Unknown 3 3.2 
CTEPH  
had surgery 
 NONE 32 65.3 
 oral monotherapy 11 22.4 
 oral dual therapy 1 2.0 
 prostenoid mono 2 4.1 
 prostenoid  oral 1 2.0 
Unclear  none 2 20.0 
 oral dual therapy 1 10.0 
 oral monotherapy 5 50.0 
 prostenoid mono 2 20.0 
 
LHD: left heart disease; PH: pulmonary hypertension; CTEPH: chronic 
thromboembolic pulmonary hypertension 
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Table S2.  Correlation of Incremental shuttle walk distance and incremental shuttle 
walk distance percent predicted with hemodynamics, WHO functional class and 
resting breathlessness 
  mRAP mPAP PVR  CO CI SmvO2 
WHO 
Class   
Borg 
rest 
All 
patients 
ISWD  
m 
r -.204** -.103* -.182** .240** .210** .220** -.558** -.403** 
p .000 .025 .000 .000 .000 .000 .000 .000 
N 478 477 464 473 466 471 477 357 
ISWD 
%pred 
r -.179** -.207** -.258** .242** .242** .235** -.583** -.391** 
p .000 .000 .000 .000 .000 .000 .000 .000 
N 478 477 464 473 466 471 477 357 
Levels 5 
Distance 
r -.216** -.117* -.196** .264** .238** .213** -.560** -.443** 
p .000 .010 .000 .000 .000 .000 .000 .000 
N 478 477 464 473 466 471 477 357 
Levels 5 
%pred 
r -.185** -.177** -.249** .256** .243** .222** -.563** -.409** 
p .000 .000 .000 .000 .000 .000 .000 .000 
N 478 477 464 473 466 471 477 357 
Group 
2 
ISWD  
m 
r -.161 -.180 -.108 .062 -.010 .204* -.587** -.385** 
p .104 .069 .279 .536 .918 .042 .000 .000 
N 103 103 102 102 101 100 103 81 
ISWD 
%pred 
r -.189 -.263** -.093 .043 .009 .179 -.563** -.414** 
p .056 .007 .350 .669 .927 .075 .000 .000 
N 103 103 102 102 101 100 103 81 
Levels 5 
Distance 
r -.193 -.156 -.110 .075 -.031 .171 -.574** -.528** 
p .051 .115 .271 .453 .759 .088 .000 .000 
N 103 103 102 102 101 100 103 81 
Levels 5 
%pred 
r -.195* -.201* -.145 .097 .040 .238* -.528** -.516** 
p .049 .041 .145 .333 .689 .017 .000 .000 
N 103 103 102 102 101 100 103 81 
Group  
3 
ISWD  
m 
r -.278** -.310** -.397** .370** .439** .159 -.582** -.317** 
p .001 .000 .000 .000 .000 .058 .000 .001 
N 147 147 143 144 142 144 146 112 
ISWD 
%pred 
r -.279** -.369** -.434** .373** .459** .124 -.603** -.314** 
p .001 .000 .000 .000 .000 .140 .000 .001 
N 147 147 143 144 142 144 146 112 
Levels 5 
Distance 
r -.255** -.336** -.438** .410** .474** .184* -.583** -.341** 
p .002 .000 .000 .000 .000 .028 .000 .000 
N 147 147 143 144 142 144 146 112 
Levels 5 
%pred 
r -.292** -.378** -.426** .404** .464** .124 -.592** -.302** 
p .000 .000 .000 .000 .000 .140 .000 .001 
N 147 147 143 144 142 144 146 112 
Group 
4 
ISWD  
m 
r -.301** -.093 -.254** .338** .303** .399** -.560** -.429** 
p .000 .188 .000 .000 .000 .000 .000 .000 
N 201 200 192 200 197 200 201 146 
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ISWD 
%pred 
r -.323** -.186** -.324** .338** .345** .458** -.574** -.400** 
p .000 .008 .000 .000 .000 .000 .000 .000 
N 201 200 192 200 197 200 201 146 
Levels 5 
Distance 
r -.295** -.108 -.258** .343** .318** .403** -.567** -.446** 
p .000 .129 .000 .000 .000 .000 .000 .000 
N 201 200 192 200 197 200 201 146 
Levels 5 
%pred 
r -.314** -.141* -.273** .303** .302** .408** -.541** -.375** 
p .000 .047 .000 .000 .000 .000 .000 .000 
N 201 200 192 200 197 200 201 146 
Group 
5 
ISWD  
m 
r .036 -.052 -.153 .488** .425* .236 -.640** -.571* 
p .858 .797 .445 .010 .031 .236 .000 .013 
N 27 27 27 27 26 27 27 18 
ISWD 
%pred 
r -.052 -.183 -.216 .531** .500** .263 -.697** -.521* 
p .798 .360 .280 .004 .009 .184 .000 .026 
N 27 27 27 27 26 27 27 18 
Levels 5 
Distance 
r .000 .021 -.033 .349 .308 .128 -.552** -.555* 
p .998 .917 .870 .074 .126 .523 .003 .017 
N 27 27 27 27 26 27 27 18 
Levels 5 
%pred 
r .061 -.117 -.152 .408* .351 .150 -.569** -.601** 
p .764 .561 .450 .035 .079 .455 .002 .008 
N 27 27 27 27 26 27 27 18 
Age 
>65 
ISWD  
m 
r -.206** -.283** -.293** .300** .276** .228** .333** -.534** 
p .001 .000 .000 .000 .000 .000 .000 .000 
N 272 272 266 270 269 268 246 272 
ISWD 
%pred 
r -.188** -.338** -.319** .266** .272** .235** .392** -.568** 
p .002 .000 .000 .000 .000 .000 .000 .000 
N 272 272 266 270 269 268 246 272 
Levels 5 
Distance 
r -.232** -.282** -.296** .307** .279** .218** .334** -.542** 
p .000 .000 .000 .000 .000 .000 .000 .000 
N 272 272 266 270 269 268 246 272 
Levels 5 
%pred 
r -.217** -.344** -.335** .291** .282** .244** .370** -.558** 
p .000 .000 .000 .000 .000 .000 .000 .000 
N 272 272 266 270 269 268 246 272 
 **. Correlation is significant at the 0.01 level (2-tailed). 
 *. Correlation is significant at the 0.05 level (2-tailed). 
 
ISWD: Incremental Shuttle Walk Test distance;  mRAP: mean right atrial 
pressure; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular 
resistance; CO: cardiac output; CI: cardiac index;  SmvO2: mixed venous oxygen 
saturation; WHO: World Health Organization 
